Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours

BACKGROUND: Genetic alterations in fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR) signalling are observed in various tumours. We report a first-in-human phase I/IIa trial evaluating tolerability, pharmacokinetics and preliminary antitumour activity o...

Descripción completa

Detalles Bibliográficos
Autores principales: Bono, Petri, Massard, Christophe, Peltola, Katriina J, Azaro, Analía, Italiano, Antoine, Kristeleit, Rebecca S, Curigliano, Giuseppe, Lassen, Ulrik, Arkenau, Hendrik-Tobias, Hakulinen, Pasi, Garratt, Chris, Ikonen, Tarja, Mustonen, Mika V J, Rodon, Jordi A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709506/
https://www.ncbi.nlm.nih.gov/pubmed/33262202
http://dx.doi.org/10.1136/esmoopen-2020-001081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709506/
https://www.ncbi.nlm.nih.gov/pubmed/33262202
http://dx.doi.org/10.1136/esmoopen-2020-001081

Ejemplares similares